Goodrx Holdings, Inc. Stock Price, News & Analysis

TherapeuticsMD (NASDAQ: TXMD) has successfully completed the $150 million divestiture of vitaCare Prescription Services to GoodRx (NASDAQ: GDRX). This strategic move, initially announced on March 6, 2022, allows TXMD to concentrate on its women's health portfolio. The company could also receive an additional $7 million based on vitaCare's 2023 financial performance. CEO Hugh O’Dowd emphasized the importance of this transaction in enhancing value for shareholders and patients.

GoodRx (GDRX) has completed its acquisition of vitaCare for $150 million in cash, plus an additional $7 million contingent on vitaCare's financial performance. This acquisition enhances GoodRx's capabilities in assisting pharmaceutical manufacturers and improving patient access to affordable medications. The deal is expected to strengthen GoodRx's Pharma Manufacturer Solutions, improving patient adherence to prescribed therapies. The company plans to address the financial impact of this acquisition during its upcoming earnings call on May 9, 2022.

GoodRx Holdings Inc. (GDRX) is set to release its Q1 2022 financial results after U.S. markets close on May 9, 2022. Management will hold a conference call at 2:00 p.m. PT to discuss the results and the company’s outlook. Interested parties can access the information via their investor relations website. GoodRx has saved consumers over $35 billion since its inception, solidifying its position as a leading digital healthcare platform.

TherapeuticsMD has agreed to divest its vitaCare Prescription Services business to GoodRx for $150 million in cash, plus up to $7 million contingent on vitaCare's 2023 performance. The deal is set to close in Q2 2022, allowing TXMD to focus on its core women's health business. CEO Hugh O’Dowd expressed confidence in GoodRx's ability to enhance patient access. TXMD will discuss this transaction in its earnings call on March 10, 2022.

GoodRx (NASDAQ: GDRX) has announced an agreement to acquire vitaCare Prescription Services from TherapeuticsMD for $150 million, plus up to $7 million contingent on performance through 2023. The acquisition aims to enhance patient access and adherence to brand medications by addressing affordability and insurance communication barriers. GoodRx expects this transaction to contribute under 1% to overall revenue and reduce adjusted EBITDA margin by about 2% in 2022, while anticipates future growth in revenue and profitability.

GoodRx Holdings has released its fourth quarter and full year 2021 financial results, highlighting its role as a leading digital healthcare platform. The company has saved consumers over $35 billion since its inception in 2011. A conference call to discuss these results is scheduled for today at 2:00 p.m. PT. Investors can access the live call and its archive on the GoodRx investor relations website.

GoodRx continues to grow as one of the most downloaded medical apps.

GoodRx Holdings has announced a new share repurchase program authorized to buy back up to $250 million of its Class A Common Stock. The program aims to enhance shareholder value and reflects the company's confidence in its future growth. Repurchases will be executed based on market conditions, using existing cash and cash equivalents, with reports indicating $941.1 million in cash available as of December 31, 2021. The program is effective immediately and may be modified or terminated by the Board at their discretion before February 23, 2024.

GoodRx Holdings Inc. (NASDAQ: GDRX) announced its participation in key investor conferences in March. Executives will present at the Raymond James 43rd Annual Institutional Investors Conference in Orlando, FL, on March 8 at 7:25 a.m. PT; at the Cowen 42nd Annual Health Care Conference virtually on March 9 at 8:10 a.m. PT; and at the Deutsche Bank 30th Annual Media, Internet & Telecom Conference in Palm Beach, FL, on March 15 at 6:35 a.m. PT. Live webcasts and archived recordings will be accessible via their Investor Relations website.

GoodRx Holdings Inc. (NASDAQ: GDRX) will release its fourth quarter and full year 2021 financial results after U.S. markets close on February 28, 2022. A conference call will occur at 2:00 p.m. PT to discuss the results and future outlook. The financial results will be available on their investor relations website. GoodRx, a leading digital healthcare platform, has helped consumers save over $35 billion since 2011, establishing itself as a crucial resource for affordable healthcare.